Overview Of HNC Market 2024: Epidemiology, Etiology, Pathophysiology, Symptoms, Diagnosis And Treatment Guidelines

"The Latest Research Report OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Head and Neck Squamous Cell Carcinoma Market

The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, with little competition from branded therapies. The market landscape is set to undergo substantial growth between 2014 and 2024. The main drivers of growth will be an increase in the diagnosed HNC population and the launch of multiple premium-priced metastatic therapies, led by the class of immuno-oncology products. Historically, cytotoxic chemotherapies have comprised the bulk of the HNC market. Little competition between targeted therapies currently exists in the HNC market, leaving an area of considerable opportunity for interested new comers. Cisplatin is the standard treatment for HNC, due to its greater efficacy over other chemotherapy agents. However, as a cytotoxic agent, its use is limited by its high toxicity and poor safety profile.

The recent investment in HNC has seen a significant increase in research activity. The launch of new agents into the market and continued innovation in the developmental pipeline promises to produce a dynamic market over the forecast period.

Highlights

Key Questions Answered

- The HNC market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the HNC market?
- The late-stage HNC pipeline is varied and innovative. Will the late-stage drugs make a significant impact on the HNC market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- The current HNC market is dominated by generic chemotherapy regimens with little branded competition. How will the advent of new targeted therapies change the treatment landscape for HNC? How will the drug treatment rate change over the next ten years? What are the key drivers and barriers to this change?

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/716928

Key Findings

- New drug launches will increase competition and drive expansion of the HNC market. Over the forecast period, six pipeline drugs are expected to file for approval in HNC and the launch of these premium priced agents will drive significant increase in total drug sales in the 7MM.
- Immuno-oncology agents will be a major driver of treatment innovation. Results from ongoing clinical trials are highly anticipated by the medical community and combination therapies hold promise of greater treatment efficacy.
- The lack of predictive biomarkers in HNC will continue to pose an issue in adopting personalized treatment, and the increasing costs of new therapies will make this a more pressing issue.
- KOLs interviewed for this report expressed a need for better treatments in earlier lines of disease in order for treatments to be effective. There needs to be an emphasis on the prevention of disease recurrence, not just treating the recurrences after they occur.

Scope

- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized HNC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global HNC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

View Report @ https://www.marketresearchreports.biz/reports/716928/opportunityanalyzer-head-and-neck-squamous-cell-carcinoma-opportunity-analysis-and-forecast-to-2024-market-research-reports

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global HNC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HNC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Track drug sales in the global HNC therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
2.3 Upcoming Related Reports 23

Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/716928

3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Biomarkers 28
3.1.3 Pathophysiology 30
3.1.4 Clinical Staging 32
3.2 Diagnosis 43
3.3 Symptoms 44
3.4 Prognosis 46
3.4.1 Quality of Life 46
4 Epidemiology 48
4.1 Risk Factors and Comorbidities 48
4.2 Global and Historical Trends 49
4.2.1 Incidence 49
4.2.2 Relative Survival - 7MM 53
4.3 Forecast Methodology 55
4.3.1 Sources Used 62
4.3.2 Sources Not Used 65
4.3.3 Forecast Assumptions and Methods 65
4.4 Epidemiological Forecast for HNC and Thyroid Cancer (2014-2024) 67
4.4.1 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 67
4.4.2 Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers 68
4.4.3 Diagnosed Incident Cases of Larynx Cancer 70
4.4.4 Diagnosed Incident Cases of HNC 71
4.4.5 Diagnosed Incident Cases of Thyroid Cancer 73
4.4.6 Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 74
4.4.7 Age-Specific Diagnosed Incident Cases of Larynx Cancer 76
4.4.8 Age-Specific Diagnosed Incident Cases of Thyroid Cancer 78
4.4.9 Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 80
4.4.10 Sex-Specific Diagnosed Incident Cases of Larynx Cancer 82
4.4.11 Sex-Specific Diagnosed Incident Cases of Thyroid Cancer 84
4.4.12 Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, and Pharynx Cancer 86
4.4.13 Age-Standardized Diagnosed Incidence of Larynx Cancer 87
4.4.14 Age-Standardized Diagnosed Incidence of Thyroid Cancer 88
4.4.15 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis 89
4.4.16 Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis 90
4.4.17 Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis 91
4.4.18 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution 92
4.4.19 Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution 93
4.4.20 Diagnosed Incident Cases of Larynx Cancer by Histology Distribution 94
4.4.21 Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution 95
4.4.22 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer 96
4.4.23 Five-Year Diagnosed Prevalent Cases of Larynx Cancer 98
4.4.24 Five-Year Diagnosed Prevalent Cases of Thyroid Cancer 99
4.5 Discussion 101
4.5.1 Epidemiological Forecast Insight 101
4.5.2 Limitations of the Analysis 101
4.5.3 Strengths of the Analysis 102
5 Current Treatment Options 103
5.1 Overview 103
5.2 Product Profiles 106
5.2.1 Erbitux (cetuximab) 106
5.2.2 TS-1 (tegafur + gimeracil + oteracil) 115
5.3 Standard of Care Chemotherapy Review 121
5.3.1 Cisplatin 121
5.3.2 Docetaxel 123
5.3.3 Fluorouracil (5-FU) 125
5.3.4 Methotrexate 125
6 Unmet Needs Assessment and Opportunity Analysis 126
6.1 Overview 126
6.2 Unmet Needs Analysis 127
6.2.1 Treatments for Recurrent and Metastatic Disease 127
6.2.2 Treatments for Locally Advanced Head and Neck Cancers 130
6.2.3 Treatments for HPV-negative Disease 132
6.2.4 Management of Co-morbidities and Adverse Events Arising from Traditional Therapy 133
6.2.5 Predictive Biomarkers to Guide and Improve the Current Treatments in Use 135
6.2.6 Investment in Non-squamous Cell Carcinomas of the Head and Neck 137

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.